SCHEMBL3205647

SCHEMBL3205647

O=C(O)c1ccc(Cl)c(-c2ccc(-c3ccncc3)cc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ABL1 P00519 1/20 0.49
ADH5 P11766 2/20 0.49
IP6K1 Q92551 1/20 0.49
IP6K3 Q96PC2 1/20 0.49
IP6K2 Q9UHH9 1/20 0.49
KMO O15229 2/20 0.48
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
GCGR P47871 1/20 0.46
MAPK14 Q16539 1/20 0.46
NAPRT Q6XQN6 1/20 0.46
SRD5A2 P31213 1/20 0.45
EIF4E P06730 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
MAP4K4 O95819 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6254017 0.86 TSHR (0.61) TSHRMEN1KMT2AADH5KMO
SCHEMBL3205630 0.85 TSHR (0.55) TSHRMEN1KMT2AKMORXRA
SCHEMBL3221130 0.84 AR (0.54) TSHRADH5KMORXRARXRB
SCHEMBL3214594 0.84 MKNK1 (0.68) ABL1IP6K1IP6K3IP6K2KMO
SCHEMBL3199834 0.83 TSHR (0.53) TSHRMEN1KMT2ARXRARXRB
SCHEMBL3207912 0.81 TSHR (0.55) TSHRKMT2AADH5KMORXRA
SCHEMBL3220340 0.81 TSHR (0.55) TSHRKMORXRARXRBSRD5A2
SCHEMBL3200062 0.81 TSHR (0.59) TSHRKMT2AKMORXRARXRB
SCHEMBL3217027 0.81 PRKAB2 (0.51) TSHRMEN1KMT2AKMORXRA
SCHEMBL3203802 0.80 TSHR (0.53) TSHRMEN1KMT2AADH5KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B TSHR 4456/4885MEN1 2335/4885KMT2A 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.